A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...
Commenting on the commission, Dr Kath McCullough, special adviser on obesity at the Royal College of Physicians, said: “For too long, we’ve relied on BMI as a simple measure of obesity, which has ...
As certain weight-loss drugs have become increasingly popular, scammers are taking notice and coming out of the woodwork to ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...
On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls.
Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback